Jose Ortega Sanchez, MD
Hematology & Oncology · Vega Baja, PRNPI 1689823452
Payments from drug & device makers
Across 962 payments — averaging $92.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$40K
- AbbVie$33K
- Johnson & Johnson$3K
- PBG Puerto Rico LLC$2K
- Amgen$1K
- Genentech USA, Inc.$1K
- plus $8K from 35 others
What the payments were for
- Food & beverage$19,37394%
- Education$1,2216%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 157 | $40,430 |
| AbbVie | 60 | $32,610 |
| Johnson & Johnson(2 entities) | 126 | $2,930 |
| PBG Puerto Rico LLC | 105 | $2,332 |
| Amgen | 69 | $1,343 |
| Genentech USA, Inc. | 62 | $1,319 |
| Eli Lilly Export S.A. Puerto Rico Branch | 54 | $1,268 |
| Merck | 53 | $1,024 |
| AstraZeneca | 43 | $748 |
| Sanofi | 33 | $715 |
| Bayer Puerto Rico Inc. | 16 | $418 |
| Eisai Inc. | 20 | $382 |
| Novartis | 15 | $379 |
| Tempus AI, Inc | 13 | $292 |
| Incyte Corporation | 7 | $292 |
| Clovis Oncology, Inc. | 10 | $249 |
| Pfizer | 10 | $232 |
| Rigel Pharmaceuticals, Inc. | 10 | $200 |
| Puma Biotechnology, Inc. | 9 | $199 |
| Bayer | 9 | $191 |
| Gilead | 8 | $177 |
| Exelixis Inc. | 8 | $154 |
| Ipsen Biopharmaceuticals, Inc | 7 | $146 |
| Array Biopharma Inc | 9 | $145 |
| Sanofi-aventis U.S. LLC | 3 | $140 |
| Taiho Oncology, Inc. | 6 | $128 |
| Jazz Pharmaceuticals Inc. | 8 | $126 |
| GSK | 4 | $111 |
| Pfizer Pharmaceuticals LLC | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Lilly USA, LLC | 3 | $63 |
| Bristol Myers Squibb | 2 | $42 |
| Sobi, Inc | 2 | $42 |
| Springworks Therapeutics, Inc. | 2 | $39 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Seagen Inc. | 1 | $20 |
| Pharmaand GmbH | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Dova Pharmaceuticals | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,251 in reported general payments places this provider in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 46 | $828,554 |
| VerzenioAbemaciclib | 44 | $682,738 |
| IbrancePalbociclib | 37 | $593,383 |
| ErleadaApalutamide | 39 | $503,131 |
| PomalystPomalidomide | 21 | $479,784 |
| KisqaliRibociclib Succinate | 25 | $444,040 |
| LynparzaOlaparib | 23 | $391,390 |
| ImbruvicaIbrutinib | 13 | $214,932 |
| TavalisseFostamatinib Disodium | 12 | $178,947 |
| PromactaEltrombopag Olamine | 11 | $169,290 |
| OpdivoNivolumab | 13 | $77,569 |
| FulphilaPegfilgrastim-Jmdb | 26 | $54,774 |
| Abiraterone Acetate | 38 | $54,133 |
| Anastrozole | 875 | $19,243 |
| EliquisApixaban | 28 | $17,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $42 | $828,55446 claims |
| Lilly USA, LLCVerzenio | $63 | $682,73844 claims |
| NovartisKisqali, Promacta | $379 | $613,33036 claims |
| PfizerIbrance, Eliquis | $232 | $610,89665 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Opdivo | $40,430 | $557,35334 claims |
| Johnson & JohnsonErleada | $2,930 | $503,13139 claims |
| AstraZenecaLynparza | $748 | $391,39023 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $200 | $178,94712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Vega Baja
- Mirelis AcostaSan Juan$6.3M
- Hector Velez CortesPonce$3.1M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Maria Garcia PallasCaguas$1.8M
- Karina Arocho-GonzalezHato Rey$1.1M
- Jose Lozada CostasSan Juan$934K
- Fernando CabanillasSan Juan$916K
- Mayra Rivera FigueroaRio Piedras$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.